254 related articles for article (PubMed ID: 29624746)
41. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
42. CEBPA double-mutated acute myeloid leukaemia harbours concomitant molecular mutations in 76·8% of cases with TET2 and GATA2 alterations impacting prognosis.
Grossmann V; Haferlach C; Nadarajah N; Fasan A; Weissmann S; Roller A; Eder C; Stopp E; Kern W; Haferlach T; Kohlmann A; Schnittger S
Br J Haematol; 2013 Jun; 161(5):649-658. PubMed ID: 23521373
[TBL] [Abstract][Full Text] [Related]
43. Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics.
Wald D; Vermaat JM; Peleg G; Tse W
Curr Hematol Malig Rep; 2008 Apr; 3(2):83-8. PubMed ID: 20425451
[TBL] [Abstract][Full Text] [Related]
44. Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.
Jan M; Snyder TM; Corces-Zimmerman MR; Vyas P; Weissman IL; Quake SR; Majeti R
Sci Transl Med; 2012 Aug; 4(149):149ra118. PubMed ID: 22932223
[TBL] [Abstract][Full Text] [Related]
45. Molecular genetics of acute myeloid leukemia: clinical implications and opportunities for integrating genomics into clinical practice.
Abdel-Wahab O
Hematology; 2012 Apr; 17 Suppl 1():S39-42. PubMed ID: 22507776
[TBL] [Abstract][Full Text] [Related]
46. Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype.
Koh Y; Park J; Bae EK; Ahn KS; Kim I; Bang SM; Lee JH; Yoon SS; Lee DS; Lee YY; Park S; Kim BK
Int J Hematol; 2009 Jul; 90(1):1-5. PubMed ID: 19484332
[TBL] [Abstract][Full Text] [Related]
47. [Clinical significance of common leukemia gene mutations in patients with acute promyelocytic leukemia].
Yin J; Sun AN; Tian XP; Tian H; Wang RX; Yang Z; Wang XL; Wu DP; Qiu HY; Pan JL; Cen JN; Liang JY; Chen SN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Feb; 21(1):39-44. PubMed ID: 23484688
[TBL] [Abstract][Full Text] [Related]
48. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome.
Wouters BJ; Löwenberg B; Erpelinck-Verschueren CA; van Putten WL; Valk PJ; Delwel R
Blood; 2009 Mar; 113(13):3088-91. PubMed ID: 19171880
[TBL] [Abstract][Full Text] [Related]
49. Abnormal expression of FLI1 protein is an adverse prognostic factor in acute myeloid leukemia.
Kornblau SM; Qiu YH; Zhang N; Singh N; Faderl S; Ferrajoli A; York H; Qutub AA; Coombes KR; Watson DK
Blood; 2011 Nov; 118(20):5604-12. PubMed ID: 21917756
[TBL] [Abstract][Full Text] [Related]
50. Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.
Nibourel O; Kosmider O; Cheok M; Boissel N; Renneville A; Philippe N; Dombret H; Dreyfus F; Quesnel B; Geffroy S; Quentin S; Roche-Lestienne C; Cayuela JM; Roumier C; Fenaux P; Vainchenker W; Bernard OA; Soulier J; Fontenay M; Preudhomme C
Blood; 2010 Aug; 116(7):1132-5. PubMed ID: 20489055
[TBL] [Abstract][Full Text] [Related]
51. Genetic biomarkers in acute myeloid leukemia: will the promise of improving treatment outcomes be realized?
Yang J; Schiffer CA
Expert Rev Hematol; 2012 Aug; 5(4):395-407. PubMed ID: 22992234
[TBL] [Abstract][Full Text] [Related]
52. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia.
Courville EL; Wu Y; Kourda J; Roth CG; Brockmann J; Muzikansky A; Fathi AT; de Leval L; Orazi A; Hasserjian RP
Mod Pathol; 2013 Jun; 26(6):751-61. PubMed ID: 23307061
[TBL] [Abstract][Full Text] [Related]
53. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
54. Impact of FLT3 ITD/NPM1 mutation status in adult patients with acute myelocytic leukemia autografted in first remission.
Gorin NC; Labopin M; Meloni G; Pigneux A; Esteve J; Mohamad M;
Haematologica; 2013 Feb; 98(2):e12-4. PubMed ID: 22929972
[No Abstract] [Full Text] [Related]
55. CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900.
Gönen M; Sun Z; Figueroa ME; Patel JP; Abdel-Wahab O; Racevskis J; Ketterling RP; Fernandez H; Rowe JM; Tallman MS; Melnick A; Levine RL; Paietta E
Blood; 2012 Sep; 120(11):2297-306. PubMed ID: 22855599
[TBL] [Abstract][Full Text] [Related]
56. Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
Balgobind BV; Hollink IH; Arentsen-Peters ST; Zimmermann M; Harbott J; Beverloo HB; von Bergh AR; Cloos J; Kaspers GJ; de Haas V; Zemanova Z; Stary J; Cayuela JM; Baruchel A; Creutzig U; Reinhardt D; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
Haematologica; 2011 Oct; 96(10):1478-87. PubMed ID: 21791472
[TBL] [Abstract][Full Text] [Related]
57. DNMT3A mutations in acute myeloid leukemia.
Ley TJ; Ding L; Walter MJ; McLellan MD; Lamprecht T; Larson DE; Kandoth C; Payton JE; Baty J; Welch J; Harris CC; Lichti CF; Townsend RR; Fulton RS; Dooling DJ; Koboldt DC; Schmidt H; Zhang Q; Osborne JR; Lin L; O'Laughlin M; McMichael JF; Delehaunty KD; McGrath SD; Fulton LA; Magrini VJ; Vickery TL; Hundal J; Cook LL; Conyers JJ; Swift GW; Reed JP; Alldredge PA; Wylie T; Walker J; Kalicki J; Watson MA; Heath S; Shannon WD; Varghese N; Nagarajan R; Westervelt P; Tomasson MH; Link DC; Graubert TA; DiPersio JF; Mardis ER; Wilson RK
N Engl J Med; 2010 Dec; 363(25):2424-33. PubMed ID: 21067377
[TBL] [Abstract][Full Text] [Related]
58. Acute myeloid leukemia with normal cytogenetics.
Mawad R; Estey EH
Curr Oncol Rep; 2012 Oct; 14(5):359-68. PubMed ID: 22806102
[TBL] [Abstract][Full Text] [Related]
59. C/EBPα and MYB regulate FLT3 expression in AML.
Volpe G; Walton DS; Del Pozzo W; Garcia P; Dassé E; O'Neill LP; Griffiths M; Frampton J; Dumon S
Leukemia; 2013 Jul; 27(7):1487-96. PubMed ID: 23340802
[TBL] [Abstract][Full Text] [Related]
60. Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics.
Gregory TK; Wald D; Chen Y; Vermaat JM; Xiong Y; Tse W
J Hematol Oncol; 2009 Jun; 2():23. PubMed ID: 19490647
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
